TriSalus Life Sciences, Inc. TLSI Proceeds from issuance of common stock relating to employee stock plans

Proceeds from issuance of common stock relating to employee stock plans at other companies

Boston ScientificBSX

$81M-29.6%

AngioDynamicsANGO

——

InfuSystem HoldingsINFU

——

LQD

Liquidia CorporationLQDA

——

Other financials

Income statement

See full

Revenue$8.9M-2.9%

Gross profit$7.7M0.0%

Operating income-$8.4M-14.8%

Net income$1.5M+115%

EPS (diluted)$0.03+108%

Balance sheet

See full

Cash & equivalents$56.6M+324%

Total debt$33.1M+4.4%

Total equity$12.8M+137%

Total assets$71.0M+148%

Cash flow

See full

Operating cash flow-$6.5M-44.0%

CapEx$141.0K-81.3%

Free cash flow-$6.6M-26.0%

Valuation

See full

Market cap$279.45M+49.6%

Enterprise value$255.97M+33.6%

P/S6.2×+1.0×

Profitability

See full

Gross margin85.1%-0.5pp

Operating margin-62.4%-16.8pp

Net margin-60.9%-13.4pp

FCF margin-45.2%-16.8pp

Returns & leverage

See full

Return on equity253.3%—

Debt / equity2.6×—

Current ratio5.8×+3.6×

Where this comes from

Reported directly by TriSalus Life Sciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: TriSalus Life Sciences, Inc.’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about TriSalus Life Sciences, Inc.'s proceeds from issuance of common stock relating to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TriSalus Life Sciences, Inc.'s proceeds from issuance of common stock relating to employee stock plans?: TriSalus Life Sciences, Inc. (TLSI) reported proceeds from issuance of common stock relating to employee stock plans of $101K in Q4 2025.
How has TriSalus Life Sciences, Inc.'s proceeds from issuance of common stock relating to employee stock plans changed year-over-year?: TriSalus Life Sciences, Inc.'s proceeds from issuance of common stock relating to employee stock plans decreased by 6.7% year-over-year, from $108.25K to $101K.